Jul 22, 2024 / 10:00AM GMT
Operator
(inaudible) is now being recorded.
Poorvank Purohit - Solara Active Pharma Sciences Ltd - Chief Executive Officer, Managing Director, Director
mainly because part of our network optimization, and you would have probably seen in our deck that was released today. We have mothballed our buyback facility and (technical difficulty) we are retrofitting that into a completely new opportunity (technical difficulty) that we are pursuing (technical difficulty) expect that in our current nature the difference between adjustment EBITDA and reported EBITDA is almost the same. It's just one line item related to certain operating cost that we are incurring, both in R&D and in our plant operations.
We also thank our shareholders for the overwhelming support and subscription to our rights issue, which was oversubscribed. Consequent to that and a key focus for the company has been to right-size our balance sheet into our working capital cycle times and cash flows, and a lot of that has been achieved already. We have used up significant opening inventories through our
Q1 2025 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Jul 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers